Drug Profile
Research programme: anti-factor XI monoclonal antibodies - Novartis
Alternative Names: NOV 1090; NOV 1401Latest Information Update: 03 Oct 2023
Price :
$50
*
At a glance
- Originator Novartis
- Class Antithrombotics; Monoclonal antibodies
- Mechanism of Action Factor XI inhibitors; Factor XIa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 03 Oct 2023 Discontinued - Preclinical for Thrombosis in Switzerland (Parenteral) (Novartis pipeline, October 2023)
- 28 Jan 2021 No recent reports of development identified for preclinical development in Thrombosis in Switzerland (Parenteral)
- 29 Dec 2016 Preclinical trials in Thrombosis in Switzerland (Parenteral) before December 2016